Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Israel KRIEGER |
Documents disponibles écrits par cet auteur (1)
Faire une suggestion Affiner la recherche
COVID-19 vaccination among individuals with autism spectrum disorder: A population-based study / Orly WEINSTEIN in Research in Autism Spectrum Disorders, 89 (November 2021)
[article]
Titre : COVID-19 vaccination among individuals with autism spectrum disorder: A population-based study Type de document : Texte imprimé et/ou numérique Auteurs : Orly WEINSTEIN, Auteur ; Israel KRIEGER, Auteur ; Arnon Dov COHEN, Auteur ; Dana TZUR BITAN, Auteur Article en page(s) : 101865 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder COVID-19 Vaccination Cohort Index. décimale : PER Périodiques Résumé : Background Individuals with autistic spectrum disorder (ASD) are more susceptible to COVID-19 morbidity and should therefore be prioritized for vaccination. Although individuals with neurodevelopmental disabilities are given some priority in Israel, it is unclear to what extent individuals with ASD are being vaccinated relative to that of the general population. This study was aimed to assess vaccination prevalence among individuals with ASD. Method Individuals with ASD, and age- and sex-matched controls (total n = 11,080), were assessed for prevalence of COVID-19 vaccination by February 2021, approximately a month and a half after the national vaccination distribution plan was launched in Israel. Data were obtained from the database of Clalit Health Services (CHS), the largest healthcare organization in Israel. Results Individuals with ASD were more likely to be vaccinated for COVID-19 (OR = 2.55, 95 %CI 2.35–2.75, p < .001) across both sexes, but only in the 16–20 (OR = 2.04, 95 %CI 1.79–2.32, p < .001) and 21?40 (OR = 3.95, 95 %CI 3.52–4.43, p < .001) age groups. After adjusting for chronic illnesses, ASD remained significant in predicting the uptake of COVID-19 vaccination. Conclusions Efforts to prioritize ASD patients may improve vaccination prevalence among individuals with ASD, especially among younger individuals. Healthcare providers worldwide should therefore consider prioritization policies so as to increase vaccination rates among this vulnerable population. En ligne : https://doi.org/10.1016/j.rasd.2021.101865 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=458
in Research in Autism Spectrum Disorders > 89 (November 2021) . - 101865[article] COVID-19 vaccination among individuals with autism spectrum disorder: A population-based study [Texte imprimé et/ou numérique] / Orly WEINSTEIN, Auteur ; Israel KRIEGER, Auteur ; Arnon Dov COHEN, Auteur ; Dana TZUR BITAN, Auteur . - 101865.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 89 (November 2021) . - 101865
Mots-clés : Autism spectrum disorder COVID-19 Vaccination Cohort Index. décimale : PER Périodiques Résumé : Background Individuals with autistic spectrum disorder (ASD) are more susceptible to COVID-19 morbidity and should therefore be prioritized for vaccination. Although individuals with neurodevelopmental disabilities are given some priority in Israel, it is unclear to what extent individuals with ASD are being vaccinated relative to that of the general population. This study was aimed to assess vaccination prevalence among individuals with ASD. Method Individuals with ASD, and age- and sex-matched controls (total n = 11,080), were assessed for prevalence of COVID-19 vaccination by February 2021, approximately a month and a half after the national vaccination distribution plan was launched in Israel. Data were obtained from the database of Clalit Health Services (CHS), the largest healthcare organization in Israel. Results Individuals with ASD were more likely to be vaccinated for COVID-19 (OR = 2.55, 95 %CI 2.35–2.75, p < .001) across both sexes, but only in the 16–20 (OR = 2.04, 95 %CI 1.79–2.32, p < .001) and 21?40 (OR = 3.95, 95 %CI 3.52–4.43, p < .001) age groups. After adjusting for chronic illnesses, ASD remained significant in predicting the uptake of COVID-19 vaccination. Conclusions Efforts to prioritize ASD patients may improve vaccination prevalence among individuals with ASD, especially among younger individuals. Healthcare providers worldwide should therefore consider prioritization policies so as to increase vaccination rates among this vulnerable population. En ligne : https://doi.org/10.1016/j.rasd.2021.101865 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=458